Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer

被引:17
|
作者
Hartung, G
Hofheinz, RD
Wein, A
Riedel, C
Rost, A
Fritze, D
Kreuser, ED
Drees, M
Kühnel, J
Hehlmann, R
Queisser, W
机构
[1] Univ Klinikum Rostock, Hamatol Onkol Abt, Klin & Poliklin Innere Med, D-18057 Rostock, Germany
[2] Univ Heidelberg, Onkol Zentrum, Med Klin 3, Univ Klinikum Mannheim, Mannheim, Germany
[3] Univ Erlangen Nurnberg, Med Klin 1, D-8520 Erlangen, Germany
[4] Klinikum Darmstadt, Med Klin 5, Darmstadt, Germany
[5] Krankenhaus Barmherzigen Bruder, Med Klin, Regensburg, Germany
[6] Medac GMBH, Wedel, Germany
来源
ONKOLOGIE | 2001年 / 24卷 / 05期
关键词
colorectal cancer; phase II study; 5-fluorouracil; calcium-folinic acid; sodium-folinic acid; weekly 24-hour infusion;
D O I
10.1159/000055126
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium - folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium - folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the simultaneous Lv. administration in combination with 5-FU in one pump. Patients and Methods; From 1997 to 1998, 51 patients [median age 60 (range 24-77) years; 38 male, 13 female] with metastatic colorectal cancer were recruited in 5 centers to receive weekly 24-hour infusions of 5-FU (2,600 mg/m(2)) and S-FA (500 mg/m(2)) dissolved in one pump for 6 weeks as first-line treatment. The treatment cycle was repeated after a 2-week rest period. Results: 1,178 administrations (median 24, range 3-54) were performed during the study. Out of 51 patients (median follow-up 20.2 months), 2 (3.9%) achieved complete remission (CR), 17 (33.3%) partial remission (PR), and 21 (41.2%) no change (NC). Progressive disease (PD) was observed in 11/51 (21.6%) patients, including 6 patients who did not complete the first cycle. Median time to tumor progression (TTP) was 8.5 months (95% Cl: 5.8-11.3). 32/51 (62.7%) patients survived for more than 1 year, the median survival was reached at 16.5 months (95%Cl: 10.2-22.8). Among major toxicities, NCL-CTC grade III/IV diarrhea occurred in 13/51 25.4%), grade III hand-foot syndrome in 6/51 (11.7% patients. Grade III/IV stomatitis was observed in 4/51 (7.8%), cardiac toxicity occurred in 2/51 patients (3.9%). Conclusion: Similar to conventional 24-hour 5-FU + CA-FA treatment, the combination with S-FA induced 37.2% objective responses with moderate toxicity. However, TTP seems favorable and the administration of S-FA is convenient, while saving costs and time for the patient in outpatient units.
引用
收藏
页码:457 / 462
页数:8
相关论文
共 50 条
  • [21] Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study
    Eric François
    Jean-François Berdah
    Emmanuel Chamorey
    Gérard Lesbats
    Eric Teissier
    Jean-François Codoul
    Jean-Luc Badetti
    Christophe Hébert
    Véronique Mari
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 931 - 936
  • [22] PHASE-I TRIAL OF 5-FLUOROURACIL BY 24-HOUR INFUSION WEEKLY
    HAAS, NB
    HINES, JB
    HUDES, GR
    JOHNSTON, N
    OZOLS, RF
    ODWYER, PJ
    INVESTIGATIONAL NEW DRUGS, 1993, 11 (2-3) : 181 - 185
  • [23] Oxaliplatin, 5-fluorouracil, and folinic acid as first-line treatment in metastatic or recurrent gastric cancer
    Kim, H.
    Yun, J.
    Kim, K.
    Kim, S.
    Lee, S.
    Bae, S.
    Lee, K.
    Hong, D.
    Park, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer?: A phase II study
    Hartmann, JT
    Köhne, CH
    Schmoll, HJ
    Daikeler, T
    Kanz, L
    Bokemeyer, C
    ONCOLOGY, 1998, 55 (04) : 320 - 325
  • [25] Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer
    Wein, A
    Riedel, C
    Brückl, W
    Merkel, S
    Ott, R
    Hanke, B
    Baum, U
    Fuchs, F
    Günther, K
    Reck, T
    Papadopoulos, T
    Hahn, EG
    Hohenberger, W
    ONCOLOGY, 2003, 64 (02) : 131 - 138
  • [26] Phase II Study of Low-dose Everolimus Plus Weekly Cisplatin and 24-hour Infusion of High-dose 5-fluorouracil and Leucovorin for First-line Treatment of Metastatic or Recurrent Gastric Cancers
    Yeh, K.
    Shen, Y. C.
    Li, C. P.
    Yen, C. J.
    Lin, Y. L.
    Lin, Z. Z.
    Chen, L. T.
    Su, W. C.
    Chao, Y.
    Cheng, A. L.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S467 - S467
  • [27] A phase II Trial of Weekly Paclitaxel, 5-Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Breast Cancer
    David M. Loesch
    Lina Asmar
    Vikki A. Canfield
    Gregory A. Parker
    Harry E. Hynes
    Peter G. Ellis
    William A. Ferri
    Nicholas J. Robert
    Breast Cancer Research and Treatment, 2003, 77 : 115 - 123
  • [28] A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer
    Loesch, DM
    Asmar, L
    Canfield, VA
    Parker, GA
    Hynes, HE
    Ellis, PG
    Ferri, WA
    Robert, NJ
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 77 (02) : 115 - 123
  • [29] Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer
    Wilke, H
    Klaassen, U
    Achterrath, W
    Losch, M
    Vanhoefer, U
    Hayungs, J
    Harstrick, A
    Stahl, M
    Eberhardt, W
    Becher, R
    Seeber, S
    ANNALS OF ONCOLOGY, 1996, 7 (01) : 55 - 58
  • [30] Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer.: A phase 2 study
    Focan, C
    Kreutz, E
    Longrée, L
    Graas, MP
    Focan-Henrard, D
    Moeneclaey, N
    David, A
    Biquet, JF
    Materne, R
    Weerts, J
    Delforge, M
    PATHOLOGIE BIOLOGIE, 2005, 53 (05): : 273 - 276